{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:27:20Z","timestamp":1790296040824,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172576"],"award-info":[{"award-number":["82172576"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172576"],"award-info":[{"award-number":["82172576"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,2,24]]},"DOI":"10.1038\/s41388-025-03598-4","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:56:49Z","timestamp":1769601409000},"page":"703-714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TBKBP1 induces capecitabine resistance through negative regulation of type I interferon pathway in triple-negative breast cancer"],"prefix":"10.1038","volume":"45","author":[{"given":"Wen-Ya","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Song","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Andriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen-Hong","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-148X","authenticated-orcid":false,"given":"Zhi-Ming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"3598_CR1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/cncr.23243","volume":"112","author":"M Brown","year":"2008","unstructured":"Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999\u20132004. Cancer. 2008;112:737\u201347.","journal-title":"Cancer"},{"key":"3598_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"3598_CR3","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1200\/JCO.19.02474","volume":"38","author":"JJ Li","year":"2020","unstructured":"Li JJ, Yu KD, Pang D, Wang CQ, Jiang J, Yang S, et al. Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase III trial. J Clin Oncol. 2020;38:1774\u201384.","journal-title":"J Clin Oncol"},{"key":"3598_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.2011.35.4639","volume":"30","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol. 2012;30:11\u20138.","journal-title":"J Clin Oncol"},{"key":"3598_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"X Wang","year":"2021","unstructured":"Wang X, Wang S, Huang H, Cai L, Zhao L, Peng R, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs. observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA. 2021;325:50\u201358.","journal-title":"JAMA"},{"key":"3598_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330\u20138.","journal-title":"Nat Rev Cancer"},{"key":"3598_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0959-8049(01)00414-2","volume":"38","author":"M Venturini","year":"2002","unstructured":"Venturini M. Rational development of capecitabine. Eur J Cancer. 2002;38:3\u20139.","journal-title":"Eur J Cancer"},{"key":"3598_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2165\/00003495-200363020-00009","volume":"63","author":"AJ Wagstaff","year":"2003","unstructured":"Wagstaff AJ, Ibbotson T, Goa KL. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs. 2003;63:217\u201336.","journal-title":"Drugs"},{"key":"3598_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111285","volume":"137","author":"C Sethy","year":"2021","unstructured":"Sethy C, Kundu CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomed Pharmacother. 2021;137:111285.","journal-title":"Biomed Pharmacother"},{"key":"3598_CR10","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.3390\/cancers12092605","volume":"12","author":"JJG Marin","year":"2020","unstructured":"Marin JJG, Macias RIR, Monte MJ, Herraez E, Peleteiro-Vigil A, de Blas BS, et al. Cellular mechanisms accounting for the refractoriness of colorectal carcinoma to pharmacological treatment. Cancers (Basel). 2020;12:2605.","journal-title":"Cancers (Basel)"},{"key":"3598_CR11","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.18632\/oncotarget.24148","volume":"9","author":"K Tecza","year":"2018","unstructured":"Tecza K, Pamula-Pilat J, Lanuszewska J, Butkiewicz D, Grzybowska E. Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget. 2018;9:9114\u201336.","journal-title":"Oncotarget"},{"key":"3598_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40170-018-0180-9","volume":"6","author":"C Bartmann","year":"2018","unstructured":"Bartmann C, Raman SRJ, Floter J, Schulze A, Bahlke K, Willingstorfer J, et al. Beta-hydroxybutyrate (3-OHB) can influence the energetic phenotype of breast cancer cells, but does not impact their proliferation and the response to chemotherapy or radiation. Cancer Metab. 2018;6:8.","journal-title":"Cancer Metab"},{"key":"3598_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.669285","volume":"9","author":"P Xie","year":"2021","unstructured":"Xie P, Yuan F, Huang M, Zhang W, Zhou H, Li X, et al. DCBLD2 affects the development of colorectal cancer via EMT and angiogenesis and modulates 5-FU drug resistance. Front Cell Dev Biol. 2021;9:669285.","journal-title":"Front Cell Dev Biol"},{"key":"3598_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.canlet.2020.10.009","volume":"497","author":"X Zheng","year":"2021","unstructured":"Zheng X, Liu J, Li X, Tian R, Shang K, Dong X, et al. Angiogenesis is promoted by exosomal DPP4 derived from 5-fluorouracil-resistant colon cancer cells. Cancer Lett. 2021;497:190\u2013201.","journal-title":"Cancer Lett"},{"key":"3598_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2675-x","volume":"11","author":"Y Yang","year":"2020","unstructured":"Yang Y, Ma L, Xu Y, Liu Y, Li W, Cai J, et al. Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-\u03baB\/STAT3-regulated proteins. Cell Death Dis. 2020;11:477.","journal-title":"Cell Death Dis"},{"key":"3598_CR16","doi-asserted-by":"publisher","first-page":"e65369","DOI":"10.1371\/journal.pone.0065369","volume":"8","author":"JM Park","year":"2013","unstructured":"Park JM, Huang SB, Tougeron D, Sinicrope FA. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. PLoS One. 2013;8:e65369.","journal-title":"PLoS One"},{"key":"3598_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10120-012-0191-0","volume":"16","author":"R Mori","year":"2013","unstructured":"Mori R, Yoshida K, Tanahashi T, Yawata K, Kato J, Okumura N, et al. Decreased FANCJ caused by 5-FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells. Gastric Cancer. 2013;16:345\u201354.","journal-title":"Gastric Cancer"},{"key":"3598_CR18","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1038\/sj.emboj.7601743","volume":"26","author":"G Ryzhakov","year":"2007","unstructured":"Ryzhakov G, Randow F. SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK. EMBO J. 2007;26:3180\u201390.","journal-title":"EMBO J"},{"key":"3598_CR19","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1007\/s00415-022-11109-8","volume":"269","author":"M Sorosina","year":"2022","unstructured":"Sorosina M, Barizzone N, Clarelli F, Anand S, Lupoli S, Salvi E, et al. A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility. J Neurol. 2022;269:4510\u201322.","journal-title":"J Neurol"},{"key":"3598_CR20","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41556-019-0429-8","volume":"21","author":"L Zhu","year":"2019","unstructured":"Zhu L, Li Y, Xie X, Zhou X, Gu M, Jie Z, et al. TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis. Nat Cell Biol. 2019;21:1604\u201314.","journal-title":"Nat Cell Biol"},{"key":"3598_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05097-5","volume":"9","author":"L Zhu","year":"2018","unstructured":"Zhu L, Xie X, Zhang L, Wang H, Jie Z, Zhou X, et al. TBK-binding protein 1 regulates IL-15-induced autophagy and NKT cell survival. Nat Commun. 2018;9:2812.","journal-title":"Nat Commun"},{"key":"3598_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20081386","volume":"417","author":"MP Murphy","year":"2009","unstructured":"Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1\u201313.","journal-title":"Biochem J"},{"key":"3598_CR23","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1080\/15548627.2019.1628548","volume":"15","author":"KB Boyle","year":"2019","unstructured":"Boyle KB, Ravenhill BJ, Randow F. CALCOCO2\/NDP52 initiates selective autophagy through recruitment of ULK and TBK1 kinase complexes. Autophagy. 2019;15:1655\u201356.","journal-title":"Autophagy"},{"key":"3598_CR24","doi-asserted-by":"publisher","first-page":"e1002247","DOI":"10.1371\/journal.ppat.1002247","volume":"7","author":"L Unterholzner","year":"2011","unstructured":"Unterholzner L, Sumner RP, Baran M, Ren H, Mansur DS, Bourke NM, et al. Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog. 2011;7:e1002247.","journal-title":"PLoS Pathog"},{"key":"3598_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17665-9","volume":"11","author":"X Lei","year":"2020","unstructured":"Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020;11:3810.","journal-title":"Nat Commun"},{"key":"3598_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115026","volume":"200","author":"MA Hamrashdi","year":"2022","unstructured":"Hamrashdi MA, Brady G. Regulation of IRF3 activation in human antiviral signaling pathways. Biochem Pharm. 2022;200:115026.","journal-title":"Biochem Pharm"},{"key":"3598_CR27","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747\u201356.","journal-title":"Genome Res"},{"key":"3598_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0893-4","volume":"17","author":"R Rosenthal","year":"2016","unstructured":"Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 2016;17:31.","journal-title":"Genome Biol"},{"key":"3598_CR29","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nprot.2012.016","volume":"7","author":"C Trapnell","year":"2012","unstructured":"Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7:562\u201378.","journal-title":"Nat Protoc"},{"key":"3598_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 2013;14:7.","journal-title":"BMC Bioinforma"},{"key":"3598_CR31","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Suvramanian","year":"2005","unstructured":"Suvramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gilette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting gegnome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3598_CR32","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"3598_CR33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019;35:428\u201340.","journal-title":"Cancer Cell"},{"key":"3598_CR34","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-18-3524","volume":"25","author":"Y Xiao","year":"2019","unstructured":"Xiao Y, Ma D, Zhao S, Suo C, Shi J, Xue M, et al. Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer. Clin Cancer Res. 2019;25:5002\u201314.","journal-title":"Clin Cancer Res"},{"key":"3598_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41591-018-0302-5","volume":"25","author":"H Liu","year":"2019","unstructured":"Liu H, Golji J, Brodeur LK, Chung FS, Chen JT, deBeaumont RS, et al. Tumor-derived IFN triggers chronic pathway agnosim and sensitivity to ADAR loss. Nat Med. 2019;25:95\u2013102.","journal-title":"Nat Med"},{"key":"3598_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"3598_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1023\/A:1006263400888","volume":"17","author":"IR Judson","year":"1999","unstructured":"Judson IR, Beale PJ, Trigo JM, Aherne W, Crompton T, Jones D, et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest N Drugs. 1999;17:49\u201356.","journal-title":"Invest N Drugs"},{"key":"3598_CR38","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.2165\/00003495-200161150-00015","volume":"61","author":"JK McGavin","year":"2001","unstructured":"McGavin JK, Goa KL. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs. 2001;61:2309\u201326.","journal-title":"Drugs"},{"key":"3598_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1012509","volume":"2022","author":"S Zhang","year":"2022","unstructured":"Zhang S, Fan S, Wang Z, Hou W, Liu T, Yoshida S, et al. Capecitabine regulates HSP90AB1 expression and induces apoptosis via AKT\/SMARCC1\/AP-1\/ROS axis in T cells. Oxid Med Cell Longev. 2022;2022:1012509.","journal-title":"Oxid Med Cell Longev"},{"key":"3598_CR40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3892\/or.2023.8612","volume":"50","author":"SM Alzahrani","year":"2023","unstructured":"Alzahrani SM, Doghaither HAA, AI-Ghafari AB, Pushparaj PN. 5-fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review). Onocl Rep. 2023;50:175.","journal-title":"Onocl Rep"},{"key":"3598_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/CJI.0b013e31824b3a76","volume":"35","author":"H Khallouf","year":"2012","unstructured":"Khallouf H, Marten A, Serba S, Teichgraber V, Buchler MW, Jager D, et al. 5-fluorouracil and interferon-\u03b1 immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I. J Immunother. 2012;35:245\u201353.","journal-title":"J Immunother"},{"key":"3598_CR42","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/ijc.11243","volume":"106","author":"S Buttiglieri","year":"2003","unstructured":"Buttiglieri S, Galetto A, Forno S, De Andrea M, Matera L. Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells. Int J Cancer. 2003;106:516\u201320.","journal-title":"Int J Cancer"},{"key":"3598_CR43","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/00001813-200311000-00010","volume":"14","author":"A Galetto","year":"2003","unstructured":"Galetto A, Buttiglieri S, Forno S, Moro F, Mussa A, Matera L. Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs. 2003;14:833\u201343.","journal-title":"Anticancer Drugs"},{"key":"3598_CR44","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","volume":"70","author":"J Vincent","year":"2010","unstructured":"Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70:3052\u201361.","journal-title":"Cancer Res"},{"key":"3598_CR45","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106065","volume":"40","author":"J Tian","year":"2021","unstructured":"Tian J, Zhang D, Kurbatov V, Wang Q, Wang Y, Fang D, et al. 5-fluorouracil efficacy requires anti-tumor immunity triggered by cancer-cell-intrinsic STING. EMBO J. 2021;40:e106065.","journal-title":"EMBO J"},{"key":"3598_CR46","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature24050","volume":"550","author":"Z Dou","year":"2017","unstructured":"Dou Z, Ghosh K, Vizioli MG, Zhu J, Sen P, Wangensteen KJ, et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature. 2017;550:402\u20136.","journal-title":"Nature"},{"key":"3598_CR47","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature23470","volume":"548","author":"SM Harding","year":"2017","unstructured":"Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017;548:466\u201370.","journal-title":"Nature"},{"key":"3598_CR48","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature23449","volume":"548","author":"KJ Mackenzie","year":"2017","unstructured":"Mackenzie KJ, Carroll P, Marin C, Murina O, Fluteau A, Simpson DJ, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548:461\u20135.","journal-title":"Nature"},{"key":"3598_CR49","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ncb3586","volume":"19","author":"S Gluck","year":"2017","unstructured":"Gluck S, Guey B, Gulen MF, Wolter K, Kang T, Schmacke NA, et al. Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. Nat Cell Biol. 2017;19:1061\u201370.","journal-title":"Nat Cell Biol"},{"key":"3598_CR50","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhao J, Zhong K, Tong A, Jia D. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther. 2022;7:113.","journal-title":"Signal Transduct Target Ther"},{"key":"3598_CR51","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1080\/15548627.2020.1712108","volume":"16","author":"DH Lee","year":"2020","unstructured":"Lee DH, Park JS, Lee YS, Han J, Lee D, Kwon SW, et al. SQSTM1\/p62 activates NFE2L2\/NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity. Autophagy. 2020;16:1949\u201373.","journal-title":"Autophagy"},{"key":"3598_CR52","doi-asserted-by":"publisher","first-page":"958","DOI":"10.21037\/jgo-22-341","volume":"13","author":"D Geng","year":"2022","unstructured":"Geng D, Wu H. Abrogation of ARF6 in promoting erastin-induced ferroptosis and mitigating capecitabine resistance in gastric cancer cells. J Gastrointest Oncol. 2022;13:958\u201367.","journal-title":"J Gastrointest Oncol"},{"key":"3598_CR53","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12865-020-00375-8","volume":"21","author":"Y Lu","year":"2020","unstructured":"Lu Y, Huang Y, Huang L, Xu Y, Wang Z, Li H, et al. CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients. BMC Immunol. 2020;21:46.","journal-title":"BMC Immunol"},{"key":"3598_CR54","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1158\/1078-0432.CCR-17-3490","volume":"24","author":"E Marangoni","year":"2018","unstructured":"Marangoni E, Laurent C, Coussy F, El-Botty R, Chateau-Joubert S, Servely J, et al. Capecitabine efficacy is correlated with TYMP and RB1 expression in PDX established from triple-negative breast cancers. Clin Cancer Res. 2018;24:2605\u201315.","journal-title":"Clin Cancer Res"},{"key":"3598_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111233","volume":"40","author":"E Pranzini","year":"2022","unstructured":"Pranzini E, Pardella E, Muccillo L, Leo A, Nesi I, Santi A, et al. SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis. Cell Rep. 2022;40:111233.","journal-title":"Cell Rep"},{"key":"3598_CR56","doi-asserted-by":"publisher","first-page":"153895","DOI":"10.1016\/j.prp.2022.153895","volume":"234","author":"Y Qu","year":"2022","unstructured":"Qu Y, Liu X, Zhao S, Zhai X. SPOCK1 silencing decreases 5-FU resistance through PRRX1 in colorectal cancer. Pathol Res Pr. 2022;234:153895.","journal-title":"Pathol Res Pr"},{"key":"3598_CR57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3892\/ijo.2022.5396","volume":"61","author":"M Li","year":"2022","unstructured":"Li M, Xia M, Zhang Z, Tan Y, Li E, Guo Z, et al. METTL3 antagonizes 5-FU chemotherapy and confers drug resistance in colorectal carcinoma. Int J Oncol. 2022;61:106.","journal-title":"Int J Oncol"},{"key":"3598_CR58","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339:786\u201391.","journal-title":"Science"},{"key":"3598_CR59","doi-asserted-by":"publisher","first-page":"8243","DOI":"10.1093\/nar\/gku569","volume":"42","author":"X Wu","year":"2014","unstructured":"Wu X, Wu F, Wang X, Wang L, Siedow JN, Zhang W, et al. Molecular evolutionary and structural analysis of the cytosolic DNA sensor cGAS and STING. Nucleic Acids Res. 2014;42:8243\u201357.","journal-title":"Nucleic Acids Res"},{"key":"3598_CR60","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature12305","volume":"498","author":"F Civril","year":"2013","unstructured":"Civril F, Deimling T, de Oliveira Mann CC, Ablasser A, Moldt M, Witte G, et al. Structural mechanism of cytosolic DNA sensing by cGAS. Nature. 2013;498:332\u20137.","journal-title":"Nature"},{"key":"3598_CR61","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nature08476","volume":"461","author":"H Ishikawa","year":"2009","unstructured":"Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009;461:788\u201392.","journal-title":"Nature"},{"key":"3598_CR62","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","volume":"17","author":"Q Chen","year":"2016","unstructured":"Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17:1142\u20139.","journal-title":"Nat Immunol"},{"key":"3598_CR63","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.immuni.2005.12.003","volume":"24","author":"DB Stetson","year":"2006","unstructured":"Stetson DB, Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity. 2006;24:93\u2013103.","journal-title":"Immunity"},{"key":"3598_CR64","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.immuni.2015.01.012","volume":"42","author":"A Hartlova","year":"2015","unstructured":"Hartlova A, Erttmann SF, Raffi FA, Schmalz AM, Resch U, Anugula S, et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote antimicrobial innate immunity. Immunity. 2015;42:332\u201343.","journal-title":"Immunity"},{"key":"3598_CR65","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1158\/0008-5472.CAN-13-1703","volume":"74","author":"AR Lam","year":"2014","unstructured":"Lam AR, Bert NL, Ho SS, Shen YJ, Tang LF, Xiong GM, et al. RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma. Cancer Res. 2014;74:2193\u2013203.","journal-title":"Cancer Res"},{"key":"3598_CR66","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1158\/2326-6066.CIR-14-0099","volume":"2","author":"T Ohkuri","year":"2014","unstructured":"Ohkuri T, Ghosh A, Kosaka A, Zhu J, Ikeura M, David M, et al. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res. 2014;2:1199\u2013208.","journal-title":"Cancer Immunol Res"},{"key":"3598_CR67","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MYK, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41:830\u201342.","journal-title":"Immunity"},{"key":"3598_CR68","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.4049\/jimmunol.1402051","volume":"193","author":"Q Zhu","year":"2014","unstructured":"Zhu Q, Man SM, Gurung P, Liu Z, Vogel P, Lamkanfi M, et al. Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. J Immunol. 2014;193:4779\u201382.","journal-title":"J Immunol"},{"key":"3598_CR69","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1371\/journal.pbio.0060301","volume":"6","author":"JP Coppe","year":"2008","unstructured":"Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:2853\u201368.","journal-title":"PLoS Biol"},{"key":"3598_CR70","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14:36\u201349.","journal-title":"Nat Rev Immunol"},{"key":"3598_CR71","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41435-020-00116-2","volume":"21","author":"M Bourden","year":"2020","unstructured":"Bourden M, Manet C, Montagutelli X. Host genetic susceptibility to viral infections: the role of type I interferon induction. Genes Immun. 2020;21:365\u201379.","journal-title":"Genes Immun"},{"key":"3598_CR72","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature07317","volume":"455","author":"H Ishikawa","year":"2008","unstructured":"Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455:674\u20138.","journal-title":"Nature"},{"key":"3598_CR73","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.immuni.2008.09.003","volume":"29","author":"B Zhong","year":"2008","unstructured":"Zhong B, Yang Y, Li S, Wang Y, Li Y, Diao F, et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity. 2008;29:538\u201350.","journal-title":"Immunity"},{"key":"3598_CR74","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1126\/science.1125676","volume":"312","author":"A Garcia-Sastre","year":"2006","unstructured":"Garcia-Sastre A, Biron CA. Type 1 interferons and the virus-host relationship: a lesson in d\u00e9tente. Science. 2006;312:879\u201382.","journal-title":"Science"},{"key":"3598_CR75","doi-asserted-by":"publisher","first-page":"528","DOI":"10.6004\/jnccn.2024.7032","volume":"22","author":"W Wu","year":"2024","unstructured":"Wu W, Yang Y, Yang W, Pang D, Liu Y, Sheng Y, et al. Tailoring escalation adjuvant therapy for early-stage triple-negative breast cancer in the CBCSG010 clinical trial biomarker analysis. J Natl Compr Canc Netw. 2024;22:528\u201336.","journal-title":"J Natl Compr Canc Netw"},{"key":"3598_CR76","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/ni.1771","volume":"10","author":"T Kawagoe","year":"2009","unstructured":"Kawagoe T, Takeuchi O, Takabatake Y, Kato H, Isaka Y, Tsujimura T, et al. TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat Immunol. 2009;10:965\u201372.","journal-title":"Nat Immunol"},{"key":"3598_CR77","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.4049\/jimmunol.1203155","volume":"190","author":"M Fukasaka","year":"2013","unstructured":"Fukasaka M, Ori D, Kawagoe T, Uematsu S, Maruyama K, Okazaki T, et al. Critical role of AZI2 in GM-CSF- induced dendritic cell differentiation. J Immunol. 2013;190:5702\u201311.","journal-title":"J Immunol"},{"key":"3598_CR78","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10:26\u201339.","journal-title":"Cancer Discov"},{"key":"3598_CR79","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1016\/j.immuni.2022.10.020","volume":"55","author":"S Lukhele","year":"2022","unstructured":"Lukhele S, Rabbo DA, Guo M, Shen J, Elsaesser HJ, Quevedo R, et al. The transcription factor IRF2 drives interferon-mediated CD8+ T cells exhaustion to restrict anti-tumor immunity. Immunity. 2022;55:2369\u201385.","journal-title":"Immunity"},{"key":"3598_CR80","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","volume":"55","author":"E Duong","year":"2022","unstructured":"Duong E, Fessenden TB, Lutz E, Dinter T, Yim L, Blatt S, et al. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Immunity. 2022;55:308\u201323.","journal-title":"Immunity"},{"key":"3598_CR81","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","volume":"18","author":"LB Ivashkiv","year":"2018","unstructured":"Ivashkiv LB. IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18:545\u201358.","journal-title":"Nat Rev Immunol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03598-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03598-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03598-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:03:24Z","timestamp":1770116604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03598-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,2,24]]}},"alternative-id":["3598"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03598-4","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Approval for the use of specimens from the CBCSG010 clinical trial was granted by independent ethics committees at each participating center. The designed animal experiments were approved by the Animal Welfare Committee of Shanghai Medical College at Fudan University (Protocol number: IACUC-2023141).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}